Cite
Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study.
MLA
Fakhouri, Fadi, et al. “Eculizumab Discontinuation in Children and Adults with Atypical Hemolytic-Uremic Syndrome: A Prospective Multicenter Study.” Blood, vol. 137, no. 18, May 2021, pp. 2438–49. EBSCOhost, https://doi.org/10.1182/blood.2020009280.
APA
Fakhouri, F., Fila, M., Hummel, A., Ribes, D., Sellier-Leclerc, A.-L., Ville, S., Pouteil-Noble, C., Coindre, J.-P., Le Quintrec, M., Rondeau, E., Boyer, O., Provôt, F., Djeddi, D., Hanf, W., Delmas, Y., Louillet, F., Lahoche, A., Favre, G., Châtelet, V., … Frémeaux-Bacchi, V. (2021). Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood, 137(18), 2438–2449. https://doi.org/10.1182/blood.2020009280
Chicago
Fakhouri, Fadi, Marc Fila, Aurélie Hummel, David Ribes, Anne-Laure Sellier-Leclerc, Simon Ville, Claire Pouteil-Noble, et al. 2021. “Eculizumab Discontinuation in Children and Adults with Atypical Hemolytic-Uremic Syndrome: A Prospective Multicenter Study.” Blood 137 (18): 2438–49. doi:10.1182/blood.2020009280.